Kasowitz Represents Triad Life Sciences in its Acquisition by ConvaTec Group

Kasowitz Benson Torres is representing medical device company Triad Life Sciences in its acquisition by ConvaTec Group, a global medical solutions company.  Under the merger agreement, which is subject to Hart-Scott-Rodino approval, ConvaTec will pay $125 million at closing, followed by two payments of $25 million each if certain short-term milestones are reached, and additional potential payments of up to $275 million if certain financial performance targets are met within the first two years.

The Kasowitz team representing Triad Life Sciences is led by partners Barry Rutcofsky and Michael D. Rosenbloom and includes associate Jacob Benson.